Kestra Advisory Services’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Kestra Advisory Services’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-16,476	Closed	-$12.2K	–	2545
2023 Q4	$12.2K	Sell	16,476 -1,500	-8%	-$1.09K	﹤0.01%	2254
2023 Q3	$15.6K	Sell	17,976 -7,507	-29%	-$9.22K	﹤0.01%	2088
2023 Q2	$47.7K	Sell	25,483 -1	-0%	-$3	﹤0.01%	2052
2023 Q1	$94.3K	Hold	25,484	–	–	﹤0.01%	1960
2022 Q4	$96.9K	Hold	25,484	–	–	﹤0.01%	2142
2022 Q3	$201K	Sell	25,484 -50	-0.2%	-$827	﹤0.01%	1877
2022 Q2	$536K	Buy	+25,534	New	+$599K	0.01%	1297

Other funds holding NBSE

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Kestra Advisory Services's NBSE Position: Q1 2024 in Review

Kestra Advisory Services sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2024, closing a stake of 16,476 shares — an estimated $12.2K sold.

Kestra Advisory Services first reported a position in NBSE in Q2 2022 and held it in 7 quarters. The position peaked at $536K in Q2 2022. 19 funds tracked by Wall St. Rank hold NBSE as of Q1 2024.

Kestra Advisory Services reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Kestra Advisory Services sold 16,476 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $12.2K.
Kestra Advisory Services first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
Kestra Advisory Services's NeuBase Therapeutics, Inc. Common Stock position peaked at $536K in Q2 2022.
19 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Kestra Advisory Services's 13F filing for Q1 2024, filed 15 May 2024.